Motofen (Mirtazapine)

Mirtazapine, the active ingredient in Motofen, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for major depressive disorder in adult patients. GNH USA supplies Motofen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine, marketed as Motofen, is indicated for conditions within the major depressive disorder therapeutic pathway.

- Major depressive disorder: alleviates depressive symptoms and improves overall mood.

Mirtazapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Edema

Serious or Rare Side Effects: - Agranulocytosis - Severe neutropenia - Hepatotoxicity - Seizures - Suicidal thoughts or behavior - Hyponatremia (low sodium levels)

Before initiating therapy, clinicians should assess patient history and monitor for specific risks. - Pregnancy: safety not established; weigh benefits against potential risks. - Breastfeeding: mirtazapine passes into milk; consider alternative therapy. - Hepatic impairment: dose adjustment may be required. - Elderly patients: increased sensitivity to sedation and falls. - Concomitant CNS depressants: monitor for enhanced sedation. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (e.g., benzodiazepines, alcohol): profound sedation. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increased mirtazapine levels.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): possible alteration of INR. - Anticholinergic agents: additive dry mouth and constipation. - Other serotonergic drugs: monitor for serotonin syndrome.